Lue Katrine Drasbæk Philipsen

Publikationer pr. år

Hvis du har foretaget ændringer i Pure, vil de snart blive vist her.

Fingeraftryk

Dyk ned i forskningsemnerne, hvor Lue Katrine Drasbæk Philipsen er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.

1 Lignende profiler

4 Tidsskriftartikel

Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor
Rysgaard, U. K., Pedersen, C. L., Jensen, J. H., Sørensen, L., Philipsen, L. K. D., Leo-Hansen, C. & Olesen, H. V., sep. 2022, I: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 21, 5, s. 844-849 6 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Use of inhaled antibiotics among Danish patients with cystic fibrosis
Møller, R., Nielsen, B. U., Faurholt-Jepsen, D., Katzenstein, T. L., Skov, M., Philipsen, L. K. D., Pressler, T., Johansen, H. K. & Qvist, T., jul. 2022, I: Pediatric Pulmonology. 57, 7, s. 1726-1734 9 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
1 Citationer (Scopus)
Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis
Voldby, C., Green, K., Philipsen, L., Sandvik, R. M., Skov, M., Buchvald, F., Pressler, T. & Nielsen, K. G., nov. 2021, I: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 20, 6, s. 949-956 8 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment
Ejiofor, L. C. K., Mathiesen, I. H. M., Jensen-Fangel, S., Olesen, H. V., Skov, M., Philipsen, L. K. D., Pedersen, C. L. & Pressler, T., dec. 2020, I: Pediatric Pulmonology. 55, 12, s. 3364-3370 7 s.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Lue Katrine Drasbæk Philipsen

Fingeraftryk

Netværk

Dyk ned i detaljerne

Change in exercise capacity measured by Cardio-pulmonary Exercise Testing (CPET) in Danish people with cystic fibrosis after initiation of treatment with Lumacaftor/Ivacaftor and Tezacaftor/Ivacaftor

Use of inhaled antibiotics among Danish patients with cystic fibrosis

Withdrawal of dornase alfa increases ventilation inhomogeneity in children with cystic fibrosis

Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment